Business
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technologyRUTHERFORD, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Victoria E. Carr-Brendel, PhD, was elected to the Company’s Board of D
About this update from Glucotrack, Inc.
[{"type":"image","alt":"Glucotrack, Inc.","displaySize":"","headline":null,"caption":"Glucotrack, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/55d126c2f85c074ae4df3a352637b3fb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RRdXPZplYJ.hxgfOveDirA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/55d126c2f85c074ae4df3a352637b3fb","width":300,"height":64}},"lazy":false},{"type":"text","content":"Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology","length":194,"tagName":"p"},{"type":"text","content":"RUTHERFORD, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Victoria E. Carr-Brendel, PhD, was elected to the Company’s Board of Directors, effective May 22, 2025.","length":339,"tagName":"p"},{"type":"text","content":"“We are delighted to welcome Dr. Carr-Brendel to Glucotrack’s Board of Directors,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “With her exceptional leadership in medical devices and deep expertise in implantable technologies, she will be an invaluable addition to the Board as we advance our continuous blood glucose monitoring (CBGM) technology through clinical development and move closer to commercialization.”","length":448,"tagName":"p"},{"type":"text","content":"Dr. Carr-Brendel currently serves as a member of the board of directors of Vicarious Surgical Inc. (NYSE: RBOT) since January 2023 and previously served from 2018 to 2024 as President and Group Vice President of Cochlear Implants at Sonova Group. Prior to that, she served as Chief Executive Officer of JenaValve Technology, Inc., a medical device company focused on developing minimally invasive transcatheter aortic valve repair systems for patients suffering from severe aortic valve disease. Previously, Dr. Carr-Brendel held various leadership roles at Boston Scientific, including overseeing the acquisition of Bayer’s interventional radiology division in 2014. She started her career as a sci...